← back to search

Kylie Prutisto-Chang

NYU Langone Health · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer therapeutics and mechanisms, and Chemical Reactions and Isotopes.
h-index
5
citations
929
works
31
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung Cancer
Clinical Cancer Research 2021cited by 137position: middledoi
Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
Annals of Oncology 2020cited by 225position: middledoi
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Clinical Cancer Research 2020cited by 193position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ibiayi Dagogo‐Jack · Center for Cancer Research2 papers (2020–2020)Satoshi Yoda · Harvard University2 papers (2020–2020)Jochen K. Lennerz · Addgene2 papers (2020–2020)Andrew Do · Global Cancer Institute2 papers (2020–2020)Justin F. Gainor · Harvard University2 papers (2020–2020)Aaron N. Hata · Harvard University2 papers (2020–2020)— · 1 papers (2020–2020)Jennifer Peterson · Jacksonville College1 papers (2020–2020)— · 1 papers (2020–2020)— · 1 papers (2020–2020)Lori J. Wirth · Harvard University1 papers (2020–2020)Adam Langenbucher · Allen Institute1 papers (2020–2020)Caroline E. McCoach · UCSF Helen Diller Family Comprehensive Cancer Center1 papers (2020–2020)Stephen V. Liu · Georgetown University1 papers (2020–2020)— · 1 papers (2020–2020)Christopher G. Azzoli · Rhode Island Hospital1 papers (2020–2020)Subba R. Digumarthy · Harvard University1 papers (2020–2020)Cyril H. Benes · Virginia Commonwealth University1 papers (2020–2020)Michael S. Lawrence · Harvard University1 papers (2020–2020)Mari Mino–Kenudson · Harvard University1 papers (2020–2020)